现代公司撤回了流感-COVID疫苗申请,在FDA要求进行新的试验后,目标是2026年获得批准. Moderna pulls flu-COVID vaccine application, targets 2026 approval after FDA demands new trials.

现代公司已撤回了对流感和COVID-19混合疫苗的申请,等待流感疫苗试验的更有效数据。 Moderna has withdrawn its application for a combined flu and COVID-19 vaccine, awaiting more efficacy data from its flu shot trial. 此项决定是根据林业发展局的要求作出的,即每年对65岁以下健康人的COVID助推器进行新的临床试验。 This decision follows the FDA's requirement for new clinical trials for annual COVID boosters for healthy individuals under 65. 现代公司现在预计将在2026年获得批准,旨在在目前的COVID疫苗销量下降的情况下从新的mRNA疫苗获得收入. Moderna now expects approval in 2026, aiming to boost revenue from newer mRNA vaccines amid declining sales of its current COVID vaccine.